Evidence map›Paper›PMID 31115244›Full record

ArticleAIDS research and human retroviruses2019

Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.

Julie J Kim-Chang, Lorena Wilson, Cliburn Chan, Bernard Fischer, Guglielmo Venturi, Maureen M Goodenow, Grace Aldrovandi, Thomas J Weber, John W Sleasman, Adolescent Medicine Trials Network for HIV/AIDS Interventions

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS research and human retroviruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Tenofovir disoproxil fumarate mediates neuronal injury by inducing neurotoxicity.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Julie J Kim-Chang1Division of Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
Lorena Wilson1Division of Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
Cliburn Chan2Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina.
Bernard Fischer1Division of Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
Guglielmo Venturi1Division of Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
Maureen M Goodenow3Molecular HIV Host Interaction Section, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
Grace Aldrovandi4Division of Infectious Diseases, Department of Pediatrics, University of California, Los Angeles, California.
Thomas J Weber5Division of Endocrinology, Metabolism and Nutrition, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
John W Sleasman1Division of Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
Adolescent Medicine Trials Network for HIV/AIDS Interventions
Duke University · USNational Institute of Allergy and Infectious Diseases · USUniversity of California, Los Angeles · US

Funding

Adol. Medicine Trials Network for HIV/AIDS InterventionsU01HD040474 · NICHD · WESTAT, INC. · PI HARRIS, DONALD ROBERT · 2001 to 2016
$114.4M
UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) GroupU01AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI JACKSON, J BROOKS · 2006 to 2010
$109.7M
LEADERSHIP GROUP FOR ADOLESCENT MEDICINE TRIALS NETWORKU01HD040533 · NICHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WILSON, CRAIG M · 2001 to 2016
$76.4M
INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR024134 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2006 to 2011
$70.4M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025780 · NCRR · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2008 to 2011
$61.3M
NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI GEORGIA Doris TOMARAS · 2005 to 2026
$50.5M
UVDM01RR010284 · NCRR · HOWARD UNIVERSITY · PI TAYLOR, ROBERT E. · 1996 to 2010
$17.4M
ZAP-70 EXPRESSION, CD38 EXPRESSION AND PROGNOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIAM01RR020359 · NCRR · CHILDREN'S RESEARCH INSTITUTE · PI MIRZA, NAZRAT · 2005 to 2010
$13.8M
RESEARCH TRAINING IN ALLERGY AND CLINICAL IMMUNOLOGYT32AI007062 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David B. Peden, John W. Sleasman · 1985 to 2026
$6.1M
Consequences of marijuana use on inflammatory pathways in HIV-infected youthU01DA044571 · NIDA · DUKE UNIVERSITY · PI SLEASMAN, JOHN W. · 2017 to 2021
$2.9M
NCATS NIH HHS UL1 TR002535NCRR NIH HHS M01 RR010284NCRR NIH HHS M01 RR020359NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1 RR025780NIAID NIH HHS P30 AI064518NIAID NIH HHS T32 AI007062NIAID NIH HHS U01 AI068632NICHD NIH HHS U01 HD040474NICHD NIH HHS U01 HD040533NIDA NIH HHS U01 DA044571
6 · The paper itself

Abstract

Both HIV infection and tenofovir disoproxil fumarate (TDF) treatment adversely impact bone metabolism and may lead to osteopenia, which has critical implications for youth with HIV (YWH). This study evaluates changes in the biomarkers of bone metabolism and inflammation among YWH receiving initial treatment with TDF- and non-TDF-containing antiretroviral therapies (ARTs). YWH [

Indexed as

AdolescentAlkaline PhosphataseAnti-HIV AgentsBiomarkersBone and BonesBone DensityBone Diseases, MetabolicFemaleHIV InfectionsHumansLymphocyte ActivationMacrophage ActivationMacrophagesMaleOsteopontinOsteoprotegerinAlkaline PhosphataseAnti-HIV AgentsBiomarkersOsteopontinOsteoprotegerinParathyroid HormoneRANK LigandTenofovirTNFSF11 protein, humanbiomarkerbone metabolismlymphocyte activationmacrophage activationtenofovir disoproxil fumarate (TDF)youth with HIV (YWH)

Identifiers

PMID31115244
PMCPMC6688113
OpenAlexW2945040112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.